What the trial was testing
The trial enrolled 1,590 patients with migraine. The study was sponsored by Pfizer and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was mid-stage testing (phase 2/3). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
People taking rimegepant had 4.3 fewer migraine days per month, compared to 3.5 fewer days with placebo.
Lancet (London, England) · 2021 · NCT03732638
These findings — that taking rimegepant every other day reduced migraine frequency by about one extra day compared to placebo — were published in the Lancet (London, England) and represent the headline result of the study.
Researchers tracked outcomes across 1,590 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with migraine, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Rimegepant (Nurtec ODT) is now FDA-approved for both treating and preventing migraines. If you have frequent migraines, talk to your doctor about whether taking this medication every other day might help reduce how often you get them. Side effects were similar to placebo in this study.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open migraine trials
Neuro-Complex & Multi Supplements for Migraine Prevention
The goal of this prospective, monocentric, open-label, non-randomized and single arm study is to evaluate a reduction of migraine days per months (MDM) by 25% by using the combined supplementation with Neuro-Complex \& Multi after 8 weeks of product intake on participants with diagnosis of migraine meeting the criteria of the International Classification of Headache Disorders (ICHD-3) (with or without aura). The main endpoint of this clinical trial is : The mean changes in migraine days per month (MDM) after 8 weeks of supplementation. Participants will: Orally consume two caps of each product (taken at the same time) daily, one in the morning and one at the lunchtime preferably during meal, for 8 weeks after a running period of 8 weeks without supplementation. Intake will be initiated from the day of follow-up visit (V1) after all study procedures being performed until the day of the end-of-study visit (V2).
Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine
This trial compares the efficacy and safety of sphenopalatine ganglion block (SPGB) and intramuscular BOTOX injection in chronic migraine.